Key Features & Benefits
Clinically relevant – Recapitulates human ITP with autoantibody-mediated platelet destruction via Fcγ receptor-mediated phagocytosis.
Quantifiable endpoint – Platelet count (PLT) measurement via automated hematology analyzer or flow cytometry.
Flexible and tunable – Acute or chronic ITP models by single or repeat antibody administration; dose escalation for prolonged thrombocytopenia.
Multiple strains – CD1 (outbred) and C57BL/6 (inbred) models available to suit different experimental needs.
Translational value – Ideal for testing thrombopoietin receptor agonists (eltrombopag, romiplostim), Fc receptor blockers (fostamatinib), and immunomodulators (IVIG, anti-CD20).
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
Technical Data & Validation
2OA-BSA Induced C57BL/6 mice PBC Model
Applications
• Efficacy testing of thrombopoietin receptor agonists (eltrombopag, romiplostim, avatrombopag)
• Evaluation of Fc receptor blockers (fostamatinib, efgartigimod) and complement inhibitors
• Testing of immunomodulators (IVIG, anti-CD20, anti-CD40L) and spleen tyrosine kinase (Syk) inhibitors
• Target validation for platelet clearance and autoimmune pathways
• IND-enabling pharmacology and toxicology studies
Model Specifications
| Parameter | CD1 Mouse ITP Model | C57BL/6 Mouse ITP Model |
| Species/Strain | CD1 mouse (outbred) | C57BL/6 mouse (inbred) |
| Induction method | Intravenous injection of anti-CD41 monoclonal antibody (e.g., MWReg30, 0.5–10 μg/g) – single dose for acute ITP, repeat doses for chronic ITP |
| Study duration | Acute: 1–7 days; Chronic: 2–4 weeks (repeat dosing) | Acute: 1–7 days; Chronic: 2–4 weeks (repeat dosing) |
| Key endpoints | Platelet count (PLT) via hematology analyzer, bleeding time, survival, optional: splenic histopathology, macrophage phenotyping |
| Positive control | IVIG (intravenous immunoglobulin) or eltrombopag available as reference compounds |
| Data package | Raw data, analysis reports, hematology results, bioinformatics (optional) |
❓ Frequently Asked Questions
Q 1: What ITP models do you provide? A1: We establish Anti-CD41 antibody induced ITP models using CD1 mice and C57BL/6 mice respectively for preclinical research of Idiopathic Thrombocytopenic Purpura.
Q2: What is the working mechanism of this ITP model? A2: Anti-CD41 antibody binds to platelets and triggers monocyte-mediated platelet destruction. By adjusting antibody dosage and administration frequency, we can simulate acute or chronic ITP conditions consistent with human pathogenesis.
Q3: What main evaluation indicators are used in the models?
A3: The core detection indicator is peripheral blood platelet (PLT) count, which directly reflects the severity of thrombocytopenia.
Q4: What is the modeling schedule for the two mouse strains?
A4: For CD1 mice, anti-CD41 antibody is injected on Day 0 and the experiment runs until the end point. For C57BL/6 mice, multiple administrations are performed from Day 0 to Day 3, and the whole study finishes on Day 7.
Q5: What are the advantages and application scope of your ITP models?
A5: This model features fast onset, stable symptoms and adjustable disease severity. It is widely used for efficacy evaluation and mechanism exploration of drugs treating immune thrombocytopenia and related bleeding disorders.
